Recursion Pharmaceuticals, Inc. RXRX Business Segments — D&A
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Recursion Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CostOfGoodsAndServicesSoldDepreciationAndAmortization.
The official record: Recursion Pharmaceuticals, Inc.’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Recursion Pharmaceuticals, Inc.'s business segments — d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Recursion Pharmaceuticals, Inc.'s business segments — D&A?
- Recursion Pharmaceuticals, Inc. (RXRX) reported business segments — D&A of $19.67M in Q1 2026.
- How has Recursion Pharmaceuticals, Inc.'s business segments — D&A changed year-over-year?
- Recursion Pharmaceuticals, Inc.'s business segments — D&A increased by 1.8% year-over-year, from $19.33M to $19.67M.
- What is the long-term trend for Recursion Pharmaceuticals, Inc.'s business segments — D&A?
- Over 3 years (2022 to 2025), Recursion Pharmaceuticals, Inc.'s business segments — D&A has grown at a 92.4% compound annual growth rate (CAGR), from $11.76M to $83.7M.
- What does business segments — D&A mean?
- Reflects the non-cash allocation of the cost of tangible and intangible assets over their useful lives within the specific business segment. It provides insight into the capital intensity of the segment and the ongoing consumption of its asset base.